Visão geral da empresa
Genenta Science S.p.A. operates as a clinical-stage biotechnology firm focused on developing hematopoietic stem cell gene therapies specifically designed to treat solid tumors within the Italian market. The company's primary therapeutic asset, Temferon, is currently undergoing Phase 1/2a clinical trials for the treatment of glioblastoma, representing a significant pipeline stage in oncology research. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, where capital-intensive research and development cycles are standard operational realities. With a total market capitalization of $15.91M and an employee base of 9, the firm demonstrates a typical micro-cap profile common to early-stage biotech ventures. These valuation metrics and the minimal workforce size suggest that the company is in a capital deployment phase where the majority of resources are directed toward advancing clinical data rather than generating commercial sales revenue or expanding operational infrastructure.
Saúde financeira
The financial statements for Genenta Science S.p.A. reflect a pre-revenue stage typical of clinical-stage biotechs, with TTM revenue and TTM earnings growth rates listed as N/A, while reporting a net income of $-6,529,827 and an EBITDA of $-6,575,658. The substantial gap between the negligible revenue figures and the significant net losses indicates a cost structure dominated by research, development, and clinical trial expenses rather than cost of goods sold or operating overhead. Free cash flow stands at $-3,095,756, which signifies that the company is burning cash to fuel its development pipeline and lacks the immediate financial flexibility to fund operations without external capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that technically reflects the absence of commercial sales revenue rather than an operational inability to manage costs efficiently. Despite the negative earnings, the balance sheet maintains a cash reserve of $28.15M against total debt of $7.60M, resulting in a debt-to-equity ratio of 34.81. The current ratio is reported at 14.15, indicating an exceptionally strong short-term liquidity position relative to current liabilities, which provides a substantial buffer for upcoming cash burn rates. Return on Equity and Return on Assets are reported at -38.0% and -17.7% respectively, metrics that reveal management is currently deploying equity and assets to generate negative returns in pursuit of long-term asset appreciation upon successful clinical trials.
Avaliação de valorização
Valuation multiples for Genenta Science S.p.A. present a complex picture due to the lack of profitability, with the P/E Ratio (TTM) listed as N/A and the Forward P/E calculated at -1.04. The negative forward P/E implies that analysts or models project future earnings that are not yet materialized, creating a theoretical discount rather than a traditional earnings-based premium. The price-to-book ratio is 0.63, suggesting that the market values the company at a discount relative to its net asset book value, a common characteristic for speculative biotech stocks awaiting clinical milestones. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to lack of sales, and the EV/EBITDA of 0.69, highlight that the company is valued based on enterprise value relative to its negative earnings power rather than traditional revenue or profit multiples. The stock has exhibited high volatility, trading between a 52-week high of $10.00 and a 52-week low of $0.59. Based on the low of $0.59 and the high of $10.00, the current trading range implies significant price discovery, though without a specific current price provided in the facts, the absolute position is defined by this wide band. The company possesses a beta of 0.71, indicating that its stock price volatility is lower than the broader market, which is somewhat atypical for small-cap biotechs but suggests a specific trading dynamic or lower liquidity profile.
Growth & Income
Genenta Science S.p.A. reports N/A for both revenue growth year-over-year and earnings growth year-over-year, metrics that are inherently uncalculable for a company with no commercial revenue. The absence of revenue growth data implies that the company is not yet in a commercial scaling phase where revenue expansion can be measured against prior periods. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, which are both listed as N/A or 0.0%, respectively. This capital allocation strategy indicates that the firm retains all potential earnings and cash reserves to reinvest directly into research and development efforts rather than rewarding shareholders with income distributions. The overall growth and income profile for Genenta Science S.p.A. is characterized by a reliance on external funding to sustain operations until the clinical development of Temferon yields results that could transition the company into a revenue-generating phase. The current financial structure prioritizes asset building over income generation, a standard trajectory for clinical-stage biotechnology firms in the healthcare sector.